An observational study in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Biogen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 9th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 125 is above the median of 108 across 266 observational studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 99 across the 9 interventional studies, 132 across the 2 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
2 of the studies in Amyotrophic Lateral Sclerosis by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07223723BiogenA Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in participant who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1.
This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using 2 different groups of study research centers that help provide clinical care for participant with ALS. These groups are in Europe and the United States and are called:
The main goal of this study is to collect safety information in participants with SOD-1 ALS who were in either of the groups.
The main question researchers want to answer in this study is:
An adverse event is a health problem that may or may not be caused by a drug during the study. An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care.
Researchers will also learn more about:
This study will be done as follows:
The primary objectives of this study are to describe demographic and clinical characteristics of participants with superoxide dismutase 1-amyotropic lateral sclerosis (SOD1-ALS); to describe the frequency of SAEs among participants with SOD1-ALS, including serious neurologic events previously reported in clinical trial participants (e.g., myelitis, radiculitis, aseptic meningitis, increased intracranial pressure, and/or papilloedema).
The secondary objectives of this study are to describe the frequency of new comorbid conditions, pregnancy and pregnancy outcome among participants with SOD1-ALS; to describe the frequency of treatment discontinuation among participants with SOD1-ALS treated with tofersen.
NHC registry has started the data collection while the Treatment Research Initiative to Cure ALS (TRICALS) is yet to start.
Participants with SOD1-ALS enrolled in TRICALS network's Precision-ALS programme with data from participating clinical centers across multiple European countries or at ALS/MND NHC with data from participating clinical centers in the United States (tofersen users and tofersen non-users).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol- defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Data for participants with SOD1-ALS will be collected via ALS disease registries, the TRICALS network's Precision-ALS programme and ALS/MND NHC.
Drug: Tofersen
Administered as specified in the treatment arm.
Also known as: BIIB067, Qalsody
Baseline Demographic: Age
Time frame: At Baseline
Baseline Demographic: Participant Sex
Time frame: At Baseline
Baseline Demographic: Race/Ethnicity
Time frame: At Baseline
Baseline Demographic: Weight
Time frame: At Baseline
Baseline Demographic: Height
Time frame: At Baseline
Baseline Demographic: Body Mass Index (BMI)
Time frame: At Baseline
Baseline Demographic: Family History of Amyotrophic Lateral Sclerosis (ALS)
Time frame: At Baseline
Clinical Characteristics: Age at Diagnosis and Symptom Onset
Time frame: At Baseline
Clinical Characteristics: Revised El Escorial Classification
Time frame: At Baseline
Clinical Characteristics: Classification of SOD1-ALS Clinical Phenotypes
Time frame: At Baseline
Clinical Characteristics: SOD1 Mutation Type
Time frame: At Baseline
Clinical Characteristics: Medical History
Time frame: At Baseline
Clinical Characteristics: Concomitant Medications
Time frame: At Baseline
Clinical Characteristics: Disease History
Time frame: At Baseline
Clinical Characteristics: Pregnancy Status
Time frame: At Baseline
Number of Participants With Serious Adverse Events
Time frame: Up to 7 years
Number of Participants With New Comorbid Conditions
Time frame: Up to 7 years
Number of Participants With Pregnancy and Pregnancy Outcomes
Time frame: Up to 7 years
Number of Participants With Reported Treatment Discontinuation
Time frame: Up to 7 years
Number of Participants With Reported Reasons for Treatment Discontinuation
Time frame: Up to 7 years
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2033, 95 months after the start.
Of 138 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 95 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →